Home
    Disclaimer
    EPT molecular structure

    EPT Stats & Data

    Ethylpropyltryptamine N,n-ethylpropyltryptamine
    NPS DataHub
    MW230.35
    FormulaC15H22N2
    IUPAC~{N}-ethyl-~{N}-[2-(1~{H}-indol-3-yl)ethyl]propan-1-amine
    SMILESCCCN(CC)CCc1cnc2ccccc12
    InChIKeyLCDYRMYSOIVPRS-UHFFFAOYSA-N
    Tryptamines; 2020/5.1 Indol-3-alkylamine; 2021/5.1 Indol-3-alkylamine; 2022/5.1 Indol-3-alkylamine
    Chemical Class Tryptamine
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT2C receptor agonist (partial)

    History & Culture

    EPT's original synthesis date remains unknown. The compound first appeared for sale on the online research chemical market in 2016, emerging as what appears to be an entirely novel product of clandestine drug design rather than a compound derived from academic or pharmaceutical research. Unlike many psychedelic tryptamines, EPT was not included in Alexander Shulgin's influential book "TiHKAL" (Tryptamines I Have Known and Loved), and the substance has no documentation in the scientific literature. EPT remains a rarely encountered psychedelic with a very limited history of human use. The compound has been identified in illicit products in Japan, though it has otherwise received minimal attention within either research contexts or broader psychedelic culture.

    Effect Profile

    Curated + 2 Reports
    Psychedelic 5.9

    Strong visuals and auditory effects with mild body load, low headspace

    Visual Intensity×3
    8
    Headspace Depth×3
    3
    Auditory Effects×1
    8
    Body Load / Somatic Effects×1
    4

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Insufflated
    4-19 minutes
    4-15 minutes
    19-40 minutes
    1-2 hours
    1-3 hours
    Oral
    30 minutes - 1.5 hours
    30 minutes - 1.0 hours
    1-2 hours
    1-2 hours
    2-4 hours
    Smoked
    1-4 minutes
    4-10 minutes
    10-30 minutes
    30 minutes - 1.5 hours
    1-2 hours

    Community Effects

    TripSit
    Negative
    nausea

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    30% ●○○
    Psilocybin
    30% ●○○
    Psilocin
    30% ●○○
    Mescaline
    30% ●○○
    DMT
    30% ●○○
    5-MeO-DMT
    30% ●○○
    2C-B
    30% ●○○
    2C-E
    30% ●○○

    Experience Report Analysis

    Erowid
    2 Reports
    2016–2017 Date Range
    2 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Legal Status

    Country Status Notes
    Germany Controlled (NpSG) Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import with intent to distribute, administration to others, and trading are criminal offenses. Personal possession is prohibited but not subject to criminal penalties.
    Italy Schedule I Listed as a controlled substance under Tabella I of Italian drug legislation. Possession, production, and distribution are prohibited.
    Switzerland Uncontrolled Not listed under Buchstabe A, B, C, or D of the Swiss controlled substances regulations. Currently considered legal, though this status may change.
    United Kingdom Class A Controlled under the Misuse of Drugs Act 1971 as a result of the tryptamine catch-all clause, which encompasses tryptamine derivatives regardless of individual scheduling. Class A substances carry the most severe penalties, including up to 7 years imprisonment for possession and life imprisonment for supply.
    United States Unscheduled Not specifically scheduled under federal law. However, due to structural similarity to DMT (a Schedule I substance), it may be subject to prosecution under the Federal Analogue Act if sold for human consumption or used for illicit purposes. Legal status may vary by state.
    ← Back to EPT